Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belatacept conversion versus continued calcineurin inhibitor therapy in adolescent kidney transplant recipients
2018-000237-12Phase 3Active
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2020
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of belatacept, tacrolimus and cyclosporine in Kidney allograft status (RTx) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Proportion of participants who survive with a functional graft and eGFR greater than 30 mL/min/1.73 m2. Started Dec 2020; status: active.
02
Drugs
belatacepttacrolimuscyclosporine
03
Conditions
Kidney allograft status (RTx)
Beyond the preview
Go deeper on 2018-000237-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000237-12.